Carboplatin and Etoposide in Previously Treated Colorectal Cancer Patients

Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J. Clin. Oncol., 10: 896–903, 1992.

Ardalan B. , Donofrio K. , Sridhar K.S. , Benedetto P. , Waldman S. , Richman S. , Reddy R. , Livingstone A. : A phase II study of short term protracted infusion of high-dose 5-fluorouracil (5-FU) with leucovorin (LV) and low dose phosphonacetyl-L-aspartic acid (PALA) in treated and untreated colorectal carcinoma. Proc. Am. Soc. Clin. Oncol., 12: 201, 1993.

Bajetta E. , Colleoni M. , Di Bartolomeo M. , Nolè F. , Nelli P. , Doci R. , de Braud F. , Gallo Stampino C. : Doxofluridine: an active agent in advanced colorectal cancer (CRC). Proc. Am. Soc. Clin. Oncol., 13: 192, 1994.

Bracarda S. , Roila F. , Crinò L. , Basurto C. , Ciccarese G. , Palladino M.A. , Meacci M. , Tonato M. : Cisplatin (CDDP), 5-fluorouracil (5-FU), folinic acid (FA) and r-interferon-alpha-2a in advanced colorectal carcinoma. A phase II study. Ann. Oncol., 3 (suppl. 5): 18, 1992.

Bugat R. , Rougier P. , Becouarn Y. , Ibrahim N. , Ychou M. , Culine S. , Extra J.M. , Adenis A. , Ganem G. , Giovannini M. , Merrouche M. , Ferrero J.F. , Conroy T. , Despax R. , Mousseau M. , Suc E. , Mathieu-Boué A. , Mahjoubi M. , Herait P. : Irinotecan (CPT-11) is an effective agent in pretreated colorectal cancer (CRC): preliminary results of multicentric phase II study. Ann. Oncol., 5 (suppl. 8): 188–189, 1994.

Bunn P.A. : Carboplatin: current status and future directions. In: Carboplatin (JM-S): Current Perspectives and Future Directions, Bunn P.A. , Canetta R. , Ozols R.F. , Rozencweig M. (eds.), pp. 371–381, WB Saunders, Philadelphia, 1990.

Conti J.A. , Kemeny N. , Goker E. , Tong W. , Colofiore J. , Andre M. , Ragusa K. , Bertino J.R. : A phase I trial of sequential trimetrexate (TMTX), fluorouracil (FU) and high-dose leucovorin (LV) in previously treated patients with gastrointestinal (GI) carcinoma. Proc. Am. Soc. Clin. Oncol., 12: 194, 1993.

De Gramont A. , Louvet C. , Varette C. , Demuynck B. , Bennamoun M. , Cady J. , Grangé J.D. , Lagadec B. , Maisani J.E. , Delfau S. , Chazouilleres O. , Loiseau J.P. , Seroka J. , Krulik M. : Reversal of resistance to high-dose folinic acid (LV) and 5-fluorouracil (5FU) in metastatic colorectal cancer by hydroxyurea. Proc. Am. Soc. Clin. Oncol., 11: 178, 1992.

Di Plama M. , Pavese I. , D'Andrea G. , Lanzillotta S. , Migliore A. , Coiro G. : Octreotide, carboplatino ed etoposide nel carcinoma del colon avanzato. Tumori, 78 (suppl): 90, 1992.

Jeremic B. , Acimovic Lj ., Djuric Lj ., Mijatovic Lj .: Carboplatin and etoposide in advanced colorectal cancer. A phase II study. Ann. Oncol., 3 (suppl. 5): 21, 1992.

Leong L. , Doroshow J. , Akman S. , Carr B. , Margolin K. , Morgan R. , Raschko J. , Somlo G. : Phase II trial of 5-FU and high dose folinic acid (FDFA) with cis-platin (CDDP) and dipyridamole (DP) in advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol., 8: 99, 1989.

Levi P. , Brienza S. , Misset J.L. , Adam S. , Kunstlinger F. , Metzger G. , Depres-Brummer P. , Le Couturier S. , Valori V. , Maoudj E. , Gastiaburu J. , Jasmin C. , Bismuth H. : Circumvention of clinical resistance of metastatic colorectal cancer to 5-fluorouracil (5-FU) with circadian-rhythm modulated venous chemotherapy. Proc. Am. Soc. Clin. Oncol., 11: 171, 1992.

Levi F. , Perpoint B. , Garufi C. , Focan Ch ., Chollet Ph ., Depres-Brummer P. , Zidani R. , Brienza S. , Itzhaki M. , Iacobelli S. , Kunstlinger F. , Gastiaburu J. , Misset J.L. : Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur. J. Cancer, 29: 1280–1284, 1993.

Marsh J.C. , Davis C. , O'Halloren K. , Duvirage H. , Voynick I. , Pasquale D. , Simonich S. , Bertino J.R. : Phase II study of 5-fluoro-2-deoxiuridine (FUdR) and leucovorin (LV) in advanced refractory colorectal cancer. Proc. Am. Soc. Clin. Oncol., 7: 107, 1988.

Miller A.B. , Hoogstraten B. , Staquet M. : Reporting results of cancer treatment. Cancer, 47: 207–214, 1981.

Nolè F. , Biganzoli L. , Buzzoni R. , Bajetta E. : Carboplatin in patients with advanced colorectal cancer pretreated with fluoropyrimidines. Eur. J. Cancer., 29A: 1330–1331, 1993.

Passalacqua R. , Bisagni G. , Cocconi G. , Boni C. , Di Blasio B. , Ceci G. : Cisplatin and etoposide in advanced colorectal cancer. Ann. Oncol., 2: 687–688, 1991.

Pazdur R.D. , Samson M.K. , Backer L.H. : CBDCA phase II evaluation in advanced colorectal carcinoma. Am. J. Clin. Oncol., 12: 416–419, 1989.

Pitot H.C. , Wender D. , O'Connell M.J. , Wieand H.S. , Maillard J.A. : A phase II trial of CPT-11 (Irinotecan) in patients with metastatic colorectal carcinoma: a North Central Cancer Treatment Group (NCCTG) study. Proc. Am. Soc. Clin. Oncol., 13: 197, 1994.

Rothenberg M.L. , Eckardt J.R. , Burris H.A. III , Nelson J. , Kuhn J.G. , Chen S.F. , Hilsenbeck S.G. , Clark G.M. , Fields S.M. , Rodriguez G.I. , Weiss G.R. , Smith L.S. , Thurman A.M. , Eckhardt S.G. , Rinald D.A. , Perez A. , von Hoff D.D. : Irinotecan (CPT-11) as second-line therapy for pts with 5-FU-refractory colorectal cancer. Proc. Am. Soc. Clin. Oncol., 13: 198, 1994.

Schmoll H.J. , Wilke H. , Schober C.H. , Stahl M. : High-dose folinic acid (HDFA)/5-fluorouracil (FU)/dipyridamole (DP)-salvage after HDFA/FU failure in colorectal cancer: a phase I study. Proc. Am. Soc. Clin. Oncol., 7: 114, 1988.

Schmoll H.J. , Gundersen S. , Arnold A. , Nys G. , Gratton R. , Canetta R. : Phase II study of carboplatin in colorectal cancer. Ann. Oncol., 1 (suppl): 48, 1990.